Valuation models
price $94.52 · as of Nov 2, 2026
DCF · Perpetuity growth · 5yused103.26 – 182.73125.5325% undervaluedDCF · Perpetuity growth · 10y114.83 – 199.90140.3433% undervaluedP/E · peers95.99 – 115.99111.3015% undervaluedP/E · own history140.15 – 390.27157.9340% undervaluedPEG—213.4156% undervaluedEV/EBITDA · peers100.80 – 241.29124.9924% undervaluedEV/Revenue · peers57.91 – 125.93103.288% undervaluedEarnings power value14.42 – 43.2225.56270% overvaluedDividend discount20.81 – 63.2232.70189% overvaluedWall St. consensus target—104.009% belowCost of capital (WACC)—6.63%—
DCF · Perpetuity growth · 5y leads for a mature, steady company — positive operating income and three years of positive free cash flow. How the headline model is chosen.
Model value · DCF · Perpetuity growth · 5y
125.53
Zimmer Biomet closed at $94.52 — undervalued by 25% vs model.
103.26the model's range182.73
DCF · Perpetuity growth · 5y leads for a mature, steady company — positive operating income and three years of positive free cash flow. From a five-year discounted cash flow.
Other models
25.56 – 213.41
Wall St. target
104.00 9% below
Below model, 1y
24 of 30 days
How it is valued
Valued asMature & stable
Low/slowing growth (~6% recent)Moderate margins (9% net margin)Pays dividendsHighly cyclical earningsStrong FCF yield (8.2%)
Model estimates for research reference only, not investment advice. Every model rests on assumptions that may not match what happens; how each model works is in the manual.